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CD28 CONTROLS DIFFERENTIATION OF REGULATORY T CELLS FROM
NAIVE CD4 T CELLS
Yu, X.-Z.1,2, Guo, F.1, Iclozan, C.1, Suh,W.-K.3, Anasetti, C.1,2 1H. Lee
Moffitt Cancer Center & Research Institute, Tampa, FL; 2University of
South Florida, Tampa, FL; 3 Institut de Recherches Cliniques de
Montreal, Montreal, QC, Canada.
CD28 is required for the development of regulatory T cells
(Tregs, CD41CD251Foxp31) in the thymus and also contributes
to their survival and homeostasis in the periphery. We studied
whether and how CD28 and ICOS control the differentiation of
Tregs from naive T cells. By using WT, CD28-, ICOS- or
CD28/ICOS-knockout mice on C57BL/6 background as T-cell
sources, we found that CD28 is essential, while ICOS is dispensable,
for the development and homeostasis of Tregs as well as for the
generation of Tregs from naive CD41CD25- T cells in vivo. The
requirement of CD28 for Treg differentiation was mediated by
IL-2, because neutralization of IL-2 with its specific mAb blocked
Treg differentiation fromwild-type CD41CD25-T cells and addi-
tion of IL-2 restored Treg differentiation from CD28-/- T cells.
Other commong-chain cytokines, IL-4, IL-7 or IL-15, do not share
such a role of IL-2. However, a strong CD28-signal promotes ex-
pansion of T effector cells (CD251Foxp3-) while inhibiting differ-
entiation of Tregs. Our study demonstrates that CD28 delicately
controls the process of Treg differentiation and T effector cell ex-
pansion in the periphery, which provides the ‘‘fine-tuning’’ of the
balance between immune activation and suppression.AUTOLOGOUS TRANSPLANTSNo Steroid
(n 5 16)
Steroid
# D12
(n 5 7)
Steroid
. D12
(n 5 7) P
P, early
vs late CS
Weight change, % 0.6 (0.4.2–6.7) 6.7 (3.6–27.2) 11.2 (22.1–23.2) 0.005 NS
Rash, % 27 71 43 NS NS
Diarrhea, % 73 86 86 NS NS
Tmax, C 39 (37.8–41) 40.1 (39–41.1) 38.9 (38.7–40.8) 0.08 0.07
1st fever, day 10 (6–15) 8 (7–9) 12 (8–146) 0.007 0.007
Abnormal CXR1, % 13 71 71 0.03 NS
Ventilator, % 0 14 71 0.004 0.03
ANC500, day 15 (12–29) 16 (14–115) 18 (15–45) 0.08 NS
PLT20, day 12 (8–41) 20 (11–115) 24 (9–170) 0.05 NS
PLT50, day 15 (11–192) 32 (16–115) 56 (13–551) 0.03 NS
RBCs, units 3 (2–8) 6 (4–31) 11 (6–64) 0.0008 NS
PLTS, apheresis units 2 (1–9) 9 (4–51) 18 (4–60) 0.0004 NS
Hospital dismissal, day 15 (13–36) 21 (15–69) 41 (16–175) 0.009 0.0586
LONG-TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANT
(ASCT) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
Al-Farsi, K., Zadeh, S., Nagy, T., Franke, N., Keating, A., Crump, M.,
Kuruvilla, J. Princess Margaret Hospital, Toronto, ON, Canada.
Introduction: MCL is considered incurable with conventional
therapy. ASCT has been shown to prolong progression free sur-
vival. However, reported median follow-up is generally short. We
report a review of the outcome of patients (pts) with MCL who un-
derwent ASCT at our institution with longer follow-up (f/u).
Method: From May 1987 – Jul 2006, 47 pts underwent ASCT
for advanced stage MCL, 43 of whom had adequate f/u data and
were subsequently analyzed for outcome. Results: At ASCT, me-
dian age: 53 years (range 34–65), 36 males, CR: 21, PR: 22. 12 pts
were transplanted beyond first CR or PR (.CR/PR1). Primary
therapy: CHOP (n5 37; R-CHOP: 9) and other combination che-
motherapy: 6. Salvage therapy in .CR/PR1: 7 had DHAP, 3
CHOP, 1 mini-BEAM and 1 ESHAP. 21 pts had rituximab before
(11 with first line or salvage and 10 with mobilizing chemotherapy)
and 11 had maintenance after ASCT. High dose regimen: CBV: 9,
VP16/Melphalan/TBI 12Gy: 27 or VP16/Melphalan: 11. Stem cell
source: peripheral blood: 40, bonemarrow: 2 andmixed: 1. Progres-
sive disease (PD) occurred in 21 pts; median time to progression
post ASCT: 25 m. 32 pts remain alive (22 in CR, 10 have relapsed),
while 11 pts have died of PD. No transplant related deaths. 4 pts de-
veloped secondary malignancies: 1 MDS, 1 skin (basal cell), 2 lung
and 1 breast cancers. With a median f/u of 57 months from ASCT,
median PFS was 42mwhile medianOS has not been reached (5 year
OS: 65%). Of pts who have not relapsed, 7 continue to be alive and
disease free. 5 years after ASCT. Univariate analysis identified the
use of rituximab before and/or after ASCT (p 5 0.047) and ASCT
inCR/PR1 (p5 0.001) as being statistically significant predictors of
improved OS with only ASCT in CR/PR1 remained significant in
multivariate analysis. For PFS, maintenance rituximab post-34ASCT (p5 0.03) and ASCT in CR/PR1 (p5 0.01) were significant
on univariate analysis with ASCT in CR/PR1 remaining significant
in themultivariatemodel (median PFS of 12m in.CR/PR1 vs. 62m
in CR/PR1, p5 0.008).Conclusion: ASCT can achieve prolonged
remissions inMCLwith some pts having remission duration of over
5 years. Pts transplanted in first remission appear to have superior
PFS and OS compared to those transplanted in later
stages. Seconds cancers may be a concern with longer follow-up.
A significant number of pts relapse after ASCT, necessitating the
exploration of more effective treatment strategies such as the incor-
poration of rituximab before and/or after ASCT.87
PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR POEMS SYNDROME
IS ASSOCIATED WITH HIGH RATES OF ENGRAFTMENT SYNDROME
Dispenzieri, A.1, Lacy, M.Q.1, Hayman, S.R.1, Kumar, S.K.1,
Buadi, F.1, Dingli, D.1, Litzow, M.R.1, Gastineau, D.A.1,
Inwards, D.J.1, Elliott, M.A.1, Micallef, I.N.1, Ansell, S.M.1,
Hogan, W.J.1, Porrata, L.F.1, Johnston, P.B.1, Afessa, B.2, Bryce, A.1,
Kyle, R.A.1, Gertz, M.A.1 1Mayo Clinic, Rochester, MN; 2Mayo Clinic,
Rochester, MN.
Background: POEMS syndrome is a devastating syndrome,
characterized by peripheral neuropathy, organomegaly, endocrin-
opathy, monoclonal plasma cells, skin changes, papilledema, vol-
ume overload, sclerotic bone lesions, thrombocytosis, and high
VEGF.High-dose chemotherapy with autologous peripheral blood
stem cell transplantation (ASCT) ultimately yields excellent clinical
responses, but there can be considerable peri-transplant morbidity.
Methods: Thirty patients with POEMS syndrome have been
treated with PBSCT at the Mayo Clinic Rochester, 11 of whom
have been previously reported. We retrospectively studied treat-
ment outcomes, with an emphasis on treatment related morbidity.
The definitions of engraftment syndrome (ES) used were of Spitzer
(BMT, 27:893–8 2001) and Maiolino et al (BMT, 31:393–397,
2003). Results: Of the 30 patients, two-thirds were male. Median
age was 48, range 20–60. The median time from the first symptoms
and from the diagnosis of POEMS syndrome was 26 and 4 months,
respectively. Patients had a median of 2 prior treatments (range 0–
6). The median number of units of RBCs and apheresis platelets
transfused were 6 and 5. During transplant period, patients had
high rates of fever, diarrhea, weight gain, and rash (93%, 77%,
53%, and 43%, respectively). Only 13% remained outpatient, and
median time to discharge from hospital was transplant day 17 (range
0–175). Factors that predicted for longer than median dismissal
times included age (p 5 0.04), abnormal chest radiograph 7 to 17
days post transplant (p\0.0001), and bolus corticosteroids beyond
day 12 post-transplant (p 5 0.006). Splenomegaly was the baseline
factor that best predicted for a complicated peri-transplant course.
Poster Session I 35Depending on the definition used, approximately 50% of patients
satisfied criteria for engraftment syndrome. Earlier and more ag-
gressive use of corticosteroids may be associated with less compli-
cated post-transplant courses. Median overall survival has not
been reached; the treatment related mortality was 3%. In addition,
important clinical improvements and reductions in plasma VEGF
levels can occur in the absence of significant decrease in the mono-
clonal protein. Conclusions: Unraveling the mechanisms of the
syndrome both in the context of ASCTand in general are challenges
for the future.88
OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
MULTIPLE MYELOMA IN PATIENTS WITH PRECEEDING PLASMA CELL
DISORDERS
Kumar, S., Dingli, D., Dispenzieri, A., Lacy, M., Hayman, S.,
Buadi, F., Rajkumar, S.V., Litzow, M.R., Gertz, M.A. Mayo Clinic,
Rochester, MN.
Background: Nearly a third of patients with newly diagnosed
myeloma (MM) have a preceding diagnosis of plasma cell prolifer-
ative disorder (PCPD), mostly monoclonal gammopathy of unde-
termined significance (MGUS), smoldering multiple myeloma
(SMM) or plasmacytoma. While high dose therapy improves sur-
vival in patients with myeloma, it is not clear if patients with preced-
ing PCPD have a different outcome. Methods and Results: We
identified 151 patients with preceding PCPD from among 804
patients undergoing high dose therapy at our institution. These
included 59 patients (7.3%) who had a preexisting diagnosis of
MGUS, 88 (11%) patients, in whom the diagnosis of MM was pre-
ceded by SMM, including 23 patients who also had a preceding
MGUSor plasmacytoma. In addition, 27 (3.4%) patients gave a pre-
ceding history of plasmacytoma. Themedian duration from the first
diagnosis of a PCPD to that of myeloma was 32.4 months (range,
6.1 to 31 years), and was longer for patients with an initial diagnosis
ofMGUS compared to those with out precedingMGUS.While re-
sponse rates including complete responses were generally similar
between the two groups of patients, those with any preceding
PCPD had a median TTP of 24.2 months (95% CI; 20, 28.3) com-
pared to 17.3 (95% CI; 15.7, 18.8) months for those with no previ-
ous history (De novo Myeloma); p 5 0.01. The median OS from
transplant for patients with previous history was 63.7 months
(95% CI; 50.2, 77.4) compared to 48.3 months (95% CI; 39.7,
56.9) for the de novo group, p 5 0.01. These differences were
most striking for those with a preceding diagnosis of MGUS; who
had a longer time to progression (27.6 months vs. 17.7 months;
p 5 0.02), and longer OS from transplant (80.2 months vs. 49.3
months, p 5 0.046) compared to those without any preceding
MGUS. In a multivariate analysis, transplant within 12 months of
diagnosis, lower serum M-protein at transplant, PCLI\1%, ab-
sence of cytogenetic abnormalities, achievement of CR, and pres-
ence of any preexisting monoclonal disorder prior to diagnosis of
myeloma were independently prognostic for risk of post transplant
relapse.Conclusion: Patients with preexisting PCPD at the time of
myeloma diagnosis undergoing HDT has a better outcome reflect-
ing more indolent disease and a favorable biology than those pre-
senting with de novo myeloma and no antecedent plasma cell
dyscrasia.89
EARLY LYMPHOCYTE RECOVERY PREDICTS SUPERIOR SURVIVAL AF-
TER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN
LYMPHOMA: A PROSPECTIVE STUDY
Porrata, L.F., Inwards, D.J., Ansell, S.M., Micallef, I.N.,
Johnston, P.B., Gastineau, D.A., Litzow, M.R., Markovic, S.N. Mayo
Clinic College of Medicine, Rochester, MN.
Background: Day 15 absolute lymphocyte count (ALC-15)
$500 cells/ml after autologous peripheral blood hematopoietic
stem cell transplantation (APHSCT) is a significant predictor for
survival. Limitations of previous reports have been their retrospec-
tive nature and no ALC-15 lymphocyte subsets analysis. Thus, from2/2002 until 2/2007, 50 non-Hodgkin lymphoma (NHL) patients
were enrolled in a prospective study to address these limitations.
Methods: APHSCT eligible NHL patients who signed written
consent for additional blood collections participated in the study.
The primary end point was to confirm the ALC-15 survival role
and to identify the lymphocyte subsets of greatest impact on
ALC-15 after APHSCT. Results: The median age of the cohort
was 57.7 years (range: 23–73). The groups (ALC-15 $500 vs\
500 cells/ml) were balanced to lymphoma type (p 5 0.4), gender
(p5 0.5), age (p5 0.2), extranodal sites (p 5 0.4), lactate dehydro-
genase (p 5 0.5), performance status (p 5 0.5), stage (p 5 0.5), in-
ternational prognostic index (p 5 0.9), number of prior
chemotherapies (p 5 0.1), clinical status at APHSCT (p 5 0.2),
and infused CD34/kg (p 5 0.8). With a median follow-up of 22.2
months (range: 6–63.7 months), patients with an ALC-15 $500
cells/ml (n5 35) experienced superior overall survival (OS) and pro-
gression-free survival (PFS) compared with those who did not (me-
dianOS: not reached vs 19months, 3 years OS rates of 80% vs 40%,
p\ 0.0004; median PFS: not reached vs 3.4 months, 3 years PFS
rates of 60% vs 14%, p\ 0.0001, respectively). By day 15 post-
APHSCT 30% of patients achieved a normal CD3, 18% a normal
CD4, 38% a normal CD8, 4% a normal CD19, and 76% a normal
[CD161/561/CD3-] counts. In Univariate analysis CD161/561/
CD3- natural killer (NK) cells were the only ALC-15 lymphocyte
subset that predicted for survival. Patients with a normal absolute
NK cell count ($80 cells/ml, n 5 38) experienced superior OS
and PFS compared with those who did not (medianOS: not reached
vs 5 months, 3 years OS rates of 76% vs 36%, p\0.0001; and me-
dian PFS: not reached vs 3 months, 3 years PFS rates of 57% vs 9%,
p \ 0.0001, respectively). Conclusion: This study confirms the
prognostic ALC-15 survival role and identifies NK cells as the
key lymphocyte subset affecting clinical outcomes after APHSCT
in NHL. This study was supported in part by the Grant
CA90628–04A from the National Institute of Health, and the Uni-
versity of Iowa/Mayo Clinic Lymphoma Spore CA97274.90
AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN FIRST REMISSION
FOR PATIENTS WITH MANTLE CELL LYMPHOMA IS ASSOCIATED WITH
PROLONGED SURVIVAL
Siddiqui, M.A., Johnston, P.B., Inwards, D.J., Ansell, S.M.,
Porrata, L.F., Micallef, I.N. Mayo Clinic, Rochester, MN.
Mantle cell lymphoma (MCL) is associated with a median sur-
vival of less than 5 years and is incurable with conventional chemo-
therapy, therefore more aggressive therapy in the form of stem cell
transplantation is often recommended. Patients receiving an autol-
ogous stem cell transplantation (ASCT) forMCLbetween 1993 and
2006 at Mayo Clinic Rochester were reviewed. 63 patients were
identified, and their baseline characteristics at diagnosis included
the following: median age 54 years (range 36–69), 51 are male, 12
are female; 55 patients had stage III or IV disease. The majority
of patients had a good PS and low IPI. Median follow up from di-
agnosis is 59.8 months (range 15 months – 20.5 years) and from
ASCT is 36.5 months (range 4months – 10.8 years). Thirty-two pa-
tients underwent ASCT in first CR/PR and 31 patients in second or
greater remission. Median overall survival (OS) from ASCT for the
patients in first remission was 91.7 months and for the patients be-
yond first remission was 35.6 months (p 5 0.01). Median OS from
diagnosis for the patients who underwent ASCT in first remission
was 103.8 months and for the patients transplanted beyond first re-
mission was 64.0 months (p 5 0.17). Median progression free sur-
vival (PFS) from ASCT was 29.6 months for the patients
transplanted in first remission vs. 15.3 months (p5 0.03) for the pa-
tients transplanted beyond first remission. Disease status at trans-
plant appears to be the most significant factor affecting survival.
Our data suggests that for patients in whom ASCT is being consid-
ered, it is advisable to proceed early in the disease (first remission)
and not wait for relapse. Demonstration of improved cohort
survival in those transplanted in first remission vs. a strategy of
transplant at chemotherapy sensitive relapse would require a ran-
domized prospective trial.
